#1 Clinical Trials Search in Europe

Diphenhydramine Hydrochloride Bp

This article examines recent clinical trials investigating the use of Diphenhydramine Hydrochloride BP in cancer treatment, particularly for lymphomas. Diphenhydramine, commonly known as an antihistamine, is being studied as a supportive medication in novel cancer therapies. The trials focus on its potential role in managing side effects and improving patient outcomes when used alongside other cancer treatments.

Table of Contents

What is Diphenhydramine Hydrochloride BP?

Diphenhydramine Hydrochloride BP is an antihistamine medication that is commonly used to treat various conditions[1]. The “BP” in its name stands for “British Pharmacopoeia,” which indicates that it meets specific quality standards. This drug is often known by its brand names, such as Benadryl, although it’s important to note that brand names can vary by country and manufacturer.

Medical Uses

Diphenhydramine Hydrochloride BP is used to treat a variety of conditions, including:

  • Allergies: It can help relieve symptoms such as sneezing, runny nose, and itchy eyes[1].
  • Insomnia: Due to its sedating effects, it’s sometimes used as a short-term sleep aid[1].
  • Motion sickness: It can help prevent and treat nausea and vomiting associated with motion sickness[1].
  • Common cold symptoms: It may help relieve some symptoms of the common cold, such as sneezing and runny nose[1].

In clinical settings, Diphenhydramine Hydrochloride BP is also used as an auxiliary medication. For example, it’s sometimes given to patients undergoing cancer treatments to help manage certain side effects[2][3].

Administration and Dosage

Diphenhydramine Hydrochloride BP can be administered in various ways:

  • Oral: It’s commonly available as tablets, capsules, or liquid formulations for oral consumption[1].
  • Intravenous (IV): In hospital settings, it may be given through an IV for faster action[2][3].

The dosage can vary depending on the condition being treated, the patient’s age, and other factors. In clinical trials, doses ranging from 25 mg to 50 mg have been used[1][3]. However, it’s crucial to follow your doctor’s instructions or the package directions carefully.

Potential Side Effects

Like all medications, Diphenhydramine Hydrochloride BP can cause side effects. Common side effects may include:

  • Drowsiness
  • Dizziness
  • Dry mouth
  • Blurred vision
  • Constipation

In rare cases, more serious side effects can occur. If you experience any unusual or severe side effects, contact your healthcare provider immediately[1].

Precautions and Considerations

When using Diphenhydramine Hydrochloride BP, keep in mind:

  • It can cause drowsiness, so avoid driving or operating machinery after taking it[1].
  • Alcohol can increase the sedative effects of this medication[1].
  • It may not be suitable for everyone, particularly those with certain medical conditions or those taking specific medications. Always consult with your healthcare provider before use[1].

Ongoing Research

While Diphenhydramine Hydrochloride BP is primarily known as an antihistamine, it’s also being studied in various clinical contexts. In some cancer treatment trials, it’s used as an auxiliary medication to help manage side effects of other treatments[2][3]. However, it’s important to note that in these contexts, it’s not being used to treat the cancer itself, but rather to support patient comfort during treatment.

As with all medications, ongoing research continues to explore its potential uses and effects. Always rely on your healthcare provider for the most up-to-date and personalized medical advice.

Trial Aspect Details
Cancer Types Studied Hodgkin lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, indolent non-Hodgkin lymphoma
Role of Diphenhydramine Hydrochloride BP Supportive medication, likely for managing side effects
Administration Methods Oral and intravenous
Maximum Daily Dose 25-50 mg (varies by trial)
Maximum Total Dose 25-650 mg (varies by trial)
Treatment Duration 1 day to 252 days (varies by trial)
Primary Objectives Evaluate efficacy and safety of primary cancer treatments
Secondary Objectives Assess pharmacokinetics, immune response, quality of life
Safety Monitoring Adverse events, lab value changes, immune responses

FAQ

  • What is Diphenhydramine Hydrochloride BP used for in these clinical trials? In these trials, Diphenhydramine Hydrochloride BP is used as a supportive medication, likely to manage side effects of cancer treatments. It's not the primary cancer treatment but helps improve patient comfort and potentially treatment effectiveness.
  • What types of cancer are being studied in these trials? The trials are primarily focused on various types of lymphomas, including Hodgkin lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, and indolent non-Hodgkin lymphoma.
  • How is Diphenhydramine Hydrochloride BP administered in these trials? The medication is administered both orally and intravenously, depending on the specific trial and treatment protocol.
  • What are the dosages of Diphenhydramine Hydrochloride BP used in these trials? The maximum daily dose mentioned is 50 mg, with a maximum total dose of 650 mg over the course of treatment in one trial. Another trial mentions a maximum daily and total dose of 25 mg.
  • Are there any side effects associated with Diphenhydramine Hydrochloride BP in these trials? While specific side effects aren't mentioned for Diphenhydramine Hydrochloride BP, the trials are monitoring for adverse events and changes in lab values. Common side effects of diphenhydramine can include drowsiness, dizziness, and dry mouth.

Ongoing Clinical Trials on Diphenhydramine Hydrochloride Bp

  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France Germany Italy The Netherlands

Glossary

  • Lymphoma: A type of cancer that begins in cells of the lymph system, which is part of the body's immune system.
  • Hodgkin lymphoma: A cancer of the lymphatic system characterized by the presence of a specific type of cell called the Reed-Sternberg cell.
  • Non-Hodgkin lymphoma: A diverse group of blood cancers that include any kind of lymphoma except Hodgkin lymphoma.
  • Mantle cell lymphoma: A rare type of non-Hodgkin lymphoma that affects the B lymphocytes in the 'mantle zone' of the lymph node.
  • Indolent non-Hodgkin lymphoma: A slow-growing type of non-Hodgkin lymphoma that typically progresses slowly and may not require immediate treatment.
  • Diphenhydramine Hydrochloride BP: An antihistamine medication used to relieve allergy symptoms and as a sleep aid. In these trials, it's being used as a supportive medication in cancer treatment.
  • Clinical trial: A research study that tests how well new medical approaches work in people, often used to evaluate new treatments for diseases like cancer.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.
  • Intravenous infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Supportive medication: Drugs used to prevent, control, or relieve complications and side effects and to improve the patient's comfort and quality of life.

References

  1. http://clinicaltrials.eu/trial/study-comparing-glofitamab-alone-to-bendamustine-with-rituximab-or-lenalidomide-with-rituximab-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gen3017-for-patients-with-relapsed-or-refractory-hodgkin-and-non-hodgkin-lymphoma/
  3. http://clinicaltrials.eu/trial/study-of-axicabtagene-ciloleucel-for-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma/